Why Australia’s unloved healthcare stocks could become the market’s next big opportunity

While investors piled into technology, artificial intelligence, and commodities, healthcare quietly became one of the worst-performing sectors on the ASX. The S&P/ASX 200 Health Care Index (XHJ) has fallen more than 50 per cent from its highs, making it one of the hardest-hit areas of the Australian market.

The question investors are now asking is simple: Has the sector finally found a bottom?

When sectors become deeply unloved, that’s often when they become interesting.

Healthcare is now sitting near a major long-term support zone after one of its sharpest declines in decades. From a technical perspective, we’re beginning to see some encouraging signs. Selling pressure appears to be easing, relative strength has stopped deteriorating, and several major healthcare names are starting to stabilise after extended downtrends.

This doesn’t mean the sector is about to enter a new bull market tomorrow.

But it does mean the risk versus reward profile is becoming far more attractive than it was 12 months ago.

What’s particularly interesting is that we’re seeing a similar set-up emerge in the United States.

The Healthcare Select Sector SPDR Fund (XLV), which tracks many of America’s largest healthcare companies, has fallen to a historic ratio support level when compared against the S&P 500.

In fact, the XLV/S&P 500 ratio is approaching levels not seen since the aftermath of the technology bubble more than two decades ago.

History never repeats perfectly. But it often rhymes.

The last time healthcare became this out of favour relative to the broader market, it eventually went on to significantly outperform as capital rotated away from crowded growth sectors and into defensive areas of the market.

What’s particularly noteworthy is that this ratio support comes at a time when investor enthusiasm remains heavily concentrated in a relatively small group of technology and AI-related stocks. If market leadership broadens over the coming years, healthcare could be one of the sectors best positioned to benefit from that rotation.

It’s impossible to discuss Australian healthcare without talking about CSL.

As the largest weighting in the healthcare index, CSL has been one of the biggest reasons the sector has struggled over the past few years. I’ve been fairly vocal on the stock throughout that period. Back in 2023, I highlighted what looked like a major distribution pattern forming, and unfortunately that’s largely how it played out.

What I got wrong was where I thought the decline would end.

I expected CSL to find a major bottom somewhere in the $140 to $160 region. Instead, the stock continued to grind lower and spent much longer in the wilderness than I anticipated.

What’s interesting now is that the investment case has changed.

For many years, CSL was viewed primarily as a growth story. Investors were willing to pay premium valuations because of what the company might become in the future. Today, the market sees CSL very differently. It’s increasingly being viewed as a value opportunity. A company with established earnings, strong cash flows, and a proven business model trading at far more reasonable valuations than we’ve seen in years.

Personally, in the current market environment, I’d rather own businesses that are already producing results than businesses that simply have the potential to produce results one day.

That seems to be one of the major themes emerging across Australian markets. The market is increasingly willing to pay for what a company does produce, not what it might produce some day. Actual earnings, cash flow, and business execution are starting to matter more than exciting narratives and distant promises.

When viewed through that lens, CSL becomes a much more interesting proposition.

From a technical perspective, the stock is beginning to stabilise around a significant support region. Momentum has improved, selling pressure appears to be fading, and buyers are gradually starting to step back in. For the first time in quite a while, the chart is starting to look constructive.

I’m not calling the all-clear just yet. Major bottoms are processes, not events.

But after several years of underperformance, CSL is showing some of the most encouraging signs I’ve seen in a long time. If healthcare is indeed starting to emerge from its bear market, CSL will likely play a major role in that recovery.

The healthcare sector remains one of the most out-of-favour areas of the market.

That’s exactly why it’s becoming interesting.

The Australian healthcare sector is sitting near major historical support after a decline of more than 50 per cent. The US healthcare sector is also testing ratio levels not seen since the beginning of the dot-com era. Meanwhile, key industry leaders such as CSL, RMD, COH, RHC and Sonic Healthcare are beginning to show early signs of life.

Will this become a major bottom?

Nobody knows for certain yet.

But some of the best opportunities in markets emerge when sentiment is poor, expectations are low, and nobody wants to talk about a sector anymore.

Healthcare isn’t there by accident. It’s there because investors have spent years abandoning it in favour of growth, technology, and AI.

The irony is that the most interesting opportunities often appear when a sector is at its most unloved.

Healthcare may not be leading the market today.

But after spending so long in the wilderness, it could be a sector worth keeping on the watch list over the months ahead.